Sage Bionetworks will partner with Pfizer to build, analyze, and exploit advanced network models of cancer. The companies hope the models will help identify therapeutic targets for oncology drug development as well as aid in evaluating the efficacy and safety of therapeutic candidates.

Pfizer will provide research funding to Sage to analyze datasets from Pfizer, Sage, and the public domain. Sage will use genetic, molecular, and clinical information to create predictive computational disease models.

This site uses Akismet to reduce spam. Learn how your comment data is processed.